Jump to content

Peter Tontonoz

Add links
From Wikipedia, the free encyclopedia
Peter Tontonoz
Occupation(s)Physician-scientist and academic
Academic background
EducationB.A. (1989)
Ph.D. (1996)
M.D. (1996)
Alma materWesleyan University
Harvard University
Harvard Medical School
Academic work
InstitutionsUniversity of California, Los Angeles

Peter Tontonoz is a physician-scientist and academic. He is the Frances and Albert Piansky Endowed Chair and Distinguished Professor of Pathology and Laboratory Medicine and of Biological Chemistry at the University of California, Los Angeles.[1]

Tontonoz's laboratory focuses on studying regulatory pathways involved in cholesterol, fatty acid, and phospholipid metabolism, contributing to uncovering fundamental mechanisms through which animals maintain cellular and whole-body lipid homeostasis. His group has clarified pathways governing lipid uptake, transport, and efflux, demonstrating their impact on the function of immune cells and metabolic tissues in both physiological and pathological conditions.[2] His h-index is 113, with over 240 research articles published and cited over 68,000 times.[3]

Tontonoz is a member of the National Academy of Sciences (NAS),[4] the National Academy of Medicine (NAM),[5] the American Society for Clinical Investigation (ASCI),[6] and the Association of American Physicians (AAP).[7] He is the recipient of national awards such as the Stanley J. Korsmeyer Award from the ASCI,[8] the ATVB Distinguished Achievement Award[9] and Jeffrey Hoeg Award from the American Heart Association (AHA),[10] as well as the Richard Weitzman Award[11] and Gerald D. Aurbach Award from The Endocrine Society.[12]

Tontonoz served as the President of the ASCI from 2013 to 2014.[6][13]

Education and early career

[edit]

Tontonoz earned his BA from Wesleyan University and his MD and PhD from Harvard Medical School's MSTP program. He completed his clinical pathology residency at the University of California, San Diego, and a postdoctoral fellowship at the Salk Institute for Biological Studies. During his time in Bruce M. Spiegelman's lab from 1990 to 1996, he discovered peroxisome proliferator-activated receptor gamma (PPAR)-γ as the key regulator of adipocyte differentiation. Following this, from 1996 to 1999, his postdoctoral work with Ronald M. Evans furthered his research in lipid signaling, connecting nuclear receptor pathways to macrophage biology and atherosclerosis.[11]

Career

[edit]

Tontonoz joined UCLA's faculty in 1999 as an assistant professor in the Department of Pathology and Laboratory Medicine, concurrently assuming the role of Investigator at the Howard Hughes Medical Institute in 2000, where he served until 2017. He was promoted to associate professor in 2002, then to Professor in 2006, and has held the position of Distinguished Professor in the Departments of Pathology and Laboratory Medicine,[14] as well as Biological Chemistry, since 2021.[15] In addition, he has been holding an appointment as a Frances and Albert Piansky Chair in Anatomy at UCLA.[16]

Research

[edit]

Tontonoz's work has focused on the regulation of cellular and systemic lipid metabolism. His research has defined new transcriptional pathways for lipid homeostasis, uncovered mechanisms of cholesterol movement in health and disease, and revealed connections between lipid metabolism, inflammation, and immunity.[4]

Tontonoz's early work on lipid-activated nuclear receptors PPAR and LXR established an understanding of the transcriptional regulation of metabolic gene networks: dietary lipids like fatty acids and sterols can directly control gene expression by binding to nuclear transcription factors. His work helped in defining LXR nuclear receptors as master regulators of the macrophage cholesterol efflux pathway.[17] His group moved on to analyze a range of LXR target genes that collaborate systematically to facilitate cellular cholesterol removal, and to demonstrate the significance of these pathways for metabolic homeostasis in vivo.[18][19][20]

Tontonoz's work also stimulated interest in LXRs as potential targets for cardiovascular disease treatment. His team was the first to establish a connection between LXR function and the development of atherosclerosis, as well as to demonstrate that synthetic LXR ligands inhibit atherogenesis in mice.[21][22] In 2003, he discovered that LXRs regulate not only cholesterol metabolism but also influence the expression of inflammatory genes.[23][24] Contributing to nuclear receptor biology, his research directed the field towards exploring links between cellular lipid metabolism and immune signaling pathways. He further uncovered significant functions of cholesterol balance in both innate and acquired immune cells, illustrating the importance of LXR transcriptional networks in macrophage reactions to bacterial pathogens and the removal of apoptotic cells. Additionally, he illustrated that disturbances in LXR signaling can result in autoimmune disease development.[25][26]

Tontonoz has utilized the LXR pathway as a roadmap to unveil mechanisms involved in lipid homeostasis. In 2009, he identified the E3 ubiquitin ligase IDOL a new mechanism for post-translational control of the LDLR. [27] He proceeded to elucidate IDOL's mode of operation, its species-specific functions in systemic cholesterol metabolism, and uncovered roles for lipoprotein receptors in Alzheimer's disease and cognitive functions such as learning and memory.[28][29][30] In addition, he has also offered insight into LXR-dependent mechanisms that merge sterol and phospholipid metabolism, ensuring membrane homeostasis. He demonstrated LXRs' key role in shaping the acyl chain composition of biological membranes by regulating the phospholipid-remodeling enzyme Lpcat3,[31] and showed that Lpcat3's ability to regulate membrane dynamics is vital for fundamental biological processes, such as the secretion of triglyceride-rich lipoproteins from the liver, absorption of dietary lipids, and proliferation of intestinal stem cells.[32][33]

In 2018, Tontonoz addressed the issue of cholesterol transport between the plasma membrane and the ER by discovering a family of three previously unidentified proteins, which he named Asters, serving as innovative intracellular sterol carriers.[34] He defined Asters as ER-resident proteins that form plasma membrane-ER contacts in response to elevated cholesterol levels in the plasma membrane, and demonstrated the critical role of Aster-B in transporting HDL-derived cholesterol from SR-BI to the ER in the adrenal cortex and liver, thus highlighting its essential function in vivo.[34][35] He further showed that Asters facilitate dietary cholesterol absorption in the intestine by acting downstream of NPC1-L1.[36]

More recently in 2023, Tontonoz identified CLSTN3β as a novel ER-lipid droplet contact protein that governs lipid utilization in adipocytes. He showed that the distinctive role of this protein in inhibiting lipid droplet coalescence resolves the question of why brown fat cells harbor numerous small lipid droplets while white fat cells possess a single large one.[37]

Awards and honors

[edit]
  • 2005 – Richard E. Weitzman Award, The Endocrine Society[11]
  • 2010 – Jeffrey M. Hoeg Award for Basic and Clinical Research, AHA[10]
  • 2014 – Gerald D. Aurbach Award, The Endocrine Society[12]
  • 2014 – Elected Member, AAP[7]
  • 2017 – Richard Havel Award Lecture, American Society for Biochemistry and Molecular Biology[38]
  • 2020 – Elected Member, NAS (USA)[4]
  • 2021 – Elected Member, NAM (USA)[39][40]
  • 2022 – Korsmeyer Award, ASCI[8]
  • 2023 – ATVB Distinguished Achievement Award, AHA[9]

Selected articles

[edit]
  • Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994). Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell, 79(7), 1147–1156.
  • Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994). mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes & development, 8(10), 1224–1234.
  • Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995). 15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell, 83(5), 803–812.
  • Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., & Evans, R. M. (1998). PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 93(2), 241–252.
  • Joseph, S. B., Castrillo, A., Laffitte, B. A., Mangelsdorf, D. J., & Tontonoz, P. (2003). Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature medicine, 9(2), 213–219.
  • Joseph, S. B., Bradley, M. N., Castrillo, A., Bruhn, K. W., Mak, P. A., Pei, L., ... & Tontonoz, P. (2004). LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell, 119(2), 299–309.
  • Tontonoz, P., & Spiegelman, B. M. (2008). Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem., 77, 289–312.
  • Zelcer, N., Hong, C., Boyadjian, R., & Tontonoz, P. (2009). LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science, 325(5936), 100–104.
  • Sandhu, J., Li, S., Fairall, L., Pfisterer, S. G., Gurnett, J. E., Xiao, X., ... & Tontonoz, P. (2018). Aster proteins facilitate nonvesicular plasma membrane to ER cholesterol transport in mammalian cells. Cell, 175(2), 514–529.
  • Ferrari, A., Whang, E., Xiao, X., Kennelly, J. P., Romartinez-Alonso, B., Mack, J. J., ... & Tontonoz, P. (2023). Aster-dependent nonvesicular transport facilitates dietary cholesterol uptake. Science, 382(6671), eadf0966.
  • Qian, K., Tol, M. J., Wu, J., Uchiyama, L. F., Xiao, X., Cui, L., Bedard, A. H., Weston, T. A., Rajendran, P. S., Vergnes, L., Shimanaka, Y., Yin, Y., Jami-Alahmadi, Y., Cohn, W., Bajar, B. T., Lin, C. H., Jin, B., DeNardo, L. A., Black, D. L., Whitelegge, J. P., ... Tontonoz, P. (2023). CLSTN3β enforces adipocyte multilocularity to facilitate lipid utilization. Nature, 613(7942), 160–168.

References

[edit]
  1. ^ "Peter Tontonoz - UCLA Profiles".
  2. ^ "Bio of Dr. Peter Tontonoz". www.uclahealth.org.
  3. ^ "Peter Tontonoz". scholar.google.com.
  4. ^ a b c "Peter Tontonoz". www.nasonline.org.
  5. ^ "National Academy of Medicine Elects 100 New Members".
  6. ^ a b "Home". The American Society for Clinical Investigation.
  7. ^ a b "Association of American Physicans". aap-online.org.
  8. ^ a b Dankoski, E. (2022). "Peter Tontonoz honored with the 2022 ASCI/Stanley J. Korsmeyer Award - PMC". The Journal of Clinical Investigation. 132 (7): e159675. doi:10.1172/JCI159675. PMC 8970667. PMID 35362484.
  9. ^ a b "Council on Arteriosclerosis, Thrombosis, and Vascular Biology Distinguished Achievement Award". professional.heart.org.
  10. ^ a b "Jeffrey M. Hoeg Arteriosclerosis, Thrombosis, and Vascular Biology Award for Basic Science and Clinical Research". professional.heart.org.
  11. ^ a b c "Endocrine Society 2014 Laureate Awards".
  12. ^ a b "ENDOCRINE SOCIETY LAUREATE AWARDS".
  13. ^ Tontonoz, Peter (July 1, 2014). "2014 American Society for Clinical Investigation Presidential AddressLeading by example: pastors, mentors, physician-scientists, and the ASCI". The Journal of Clinical Investigation. 124 (7): 2816–2821. doi:10.1172/JCI77200. PMC 4071402. PMID 24983420 – via www.jci.org.
  14. ^ "Peter Tontonoz, MD, PhD". www.uclahealth.org.
  15. ^ "Peter Tontonoz - Department of Biological Chemistry".
  16. ^ "Endowed Chairs, Presidential Chairs, Professorial Name Chairs". Academic Affairs and Personnel. June 12, 2017.
  17. ^ Venkateswaran, A.; Laffitte, B. A.; Joseph, S. B.; Mak, P. A.; Wilpitz, D. C.; Edwards, P. A.; Tontonoz, P. (October 24, 2000). "Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha". Proceedings of the National Academy of Sciences of the United States of America. 97 (22): 12097–12102. doi:10.1073/pnas.200367697. PMC 17300. PMID 11035776.
  18. ^ Ba, Laffitte; Jj, Repa; Sb, Joseph; Dc, Wilpitz; Hr, Kast; Dj, Mangelsdorf; P, Tontonoz (January 16, 2001). "LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes". Proceedings of the National Academy of Sciences of the United States of America. 98 (2): 507–512. doi:10.1073/pnas.98.2.507. PMC 14617. PMID 11149950.
  19. ^ Chawla, A.; Boisvert, W. A.; Lee, C. H.; Laffitte, B. A.; Barak, Y.; Joseph, S. B.; Liao, D.; Nagy, L.; Edwards, P. A.; Curtiss, L. K.; Evans, R. M.; Tontonoz, P. (January 19, 2001). "A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis". Molecular Cell. 7 (1): 161–171. doi:10.1016/s1097-2765(01)00164-2. PMID 11172721.
  20. ^ Laffitte, Bryan A.; Chao, Lily C.; Li, Jing; Walczak, Robert; Hummasti, Sarah; Joseph, Sean B.; Castrillo, Antonio; Wilpitz, Damien C.; Mangelsdorf, David J.; Collins, Jon L.; Saez, Enrique; Tontonoz, Peter (April 29, 2003). "Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue". Proceedings of the National Academy of Sciences of the United States of America. 100 (9): 5419–5424. doi:10.1073/pnas.0830671100. PMC 154360. PMID 12697904.
  21. ^ Tangirala, Rajendra K.; Bischoff, Eric D.; Joseph, Sean B.; Wagner, Brandee L.; Walczak, Robert; Laffitte, Bryan A.; Daige, Chris L.; Thomas, Diane; Heyman, Richard A.; Mangelsdorf, David J.; Wang, Xuping; Lusis, Aldons J.; Tontonoz, Peter; Schulman, Ira G. (September 3, 2002). "Identification of macrophage liver X receptors as inhibitors of atherosclerosis". Proceedings of the National Academy of Sciences of the United States of America. 99 (18): 11896–11901. doi:10.1073/pnas.182199799. PMC 129365. PMID 12193651.
  22. ^ Joseph, Sean B.; McKilligin, Elaine; Pei, Liming; Watson, Michael A.; Collins, Alan R.; Laffitte, Bryan A.; Chen, Mingyi; Noh, Grace; Goodman, Joanne; Hagger, Graham N.; Tran, Jonathan; Tippin, Tim K.; Wang, Xuping; Lusis, Aldons J.; Hsueh, Willa A.; Law, Ronald E.; Collins, Jon L.; Willson, Timothy M.; Tontonoz, Peter (May 28, 2002). "Synthetic LXR ligand inhibits the development of atherosclerosis in mice". Proceedings of the National Academy of Sciences of the United States of America. 99 (11): 7604–7609. doi:10.1073/pnas.112059299. PMC 124297. PMID 12032330.
  23. ^ Joseph, Sean B.; Castrillo, Antonio; Laffitte, Bryan A.; Mangelsdorf, David J.; Tontonoz, Peter (February 19, 2003). "Reciprocal regulation of inflammation and lipid metabolism by liver X receptors". Nature Medicine. 9 (2): 213–219. doi:10.1038/nm820. PMID 12524534 – via PubMed.
  24. ^ A, Castrillo; Sb, Joseph; Sa, Vaidya; M, Haberland; Am, Fogelman; G, Cheng; P, Tontonoz (October 19, 2003). "Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism". Molecular Cell. 12 (4): 805–816. doi:10.1016/s1097-2765(03)00384-8. PMID 14580333.
  25. ^ Joseph, Sean B.; Bradley, Michelle N.; Castrillo, Antonio; Bruhn, Kevin W.; Mak, Puiying A.; Pei, Liming; Hogenesch, John; O'connell, Ryan M.; Cheng, Genhong; Saez, Enrique; Miller, Jeffery F.; Tontonoz, Peter (October 15, 2004). "LXR-dependent gene expression is important for macrophage survival and the innate immune response". Cell. 119 (2): 299–309. doi:10.1016/j.cell.2004.09.032. PMID 15479645.
  26. ^ a-Gonzalez, N.; Bensinger, S. J.; Hong, C.; Beceiro, S.; Bradley, M. N.; Zelcer, N.; Deniz, J.; Ramirez, C.; Díaz, M.; Gallardo, G.; De Galarreta, C. R.; Salazar, J.; Lopez, F.; Edwards, P.; Parks, J.; Andujar, M.; Tontonoz, P.; Castrillo, A. (2009). "Apoptotic cells promote their own clearance and immune tolerance through activation of LXR - PMC". Immunity. 31 (2): 245–258. doi:10.1016/j.immuni.2009.06.018. PMC 2791787. PMID 19646905.
  27. ^ Zelcer, Noam; Hong, Cynthia; Boyadjian, Rima; Tontonoz, Peter (July 3, 2009). "LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor". Science. 325 (5936): 100–104. doi:10.1126/science.1168974. PMC 2777523. PMID 19520913.
  28. ^ Calkin, Anna C.; Goult, Benjamin T.; Zhang, Li; Fairall, Louise; Hong, Cynthia; Schwabe, John W. R.; Tontonoz, Peter (December 13, 2011). "FERM-dependent E3 ligase recognition is a conserved mechanism for targeted degradation of lipoprotein receptors". Proceedings of the National Academy of Sciences of the United States of America. 108 (50): 20107–20112. doi:10.1073/pnas.1111589108. PMC 3250164. PMID 22109552.
  29. ^ Hong, Cynthia; Marshall, Stephanie M.; McDaniel, Allison L.; Graham, Mark; Layne, Joseph D.; Cai, Lei; Scotti, Elena; Boyadjian, Rima; Kim, Jason; Chamberlain, Brian T.; Tangirala, Rajendra K.; Jung, Michael E.; Fong, Loren; Lee, Richard; Young, Stephen G.; Temel, Ryan E.; Tontonoz, Peter (November 4, 2014). "The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice". Cell Metabolism. 20 (5): 910–918. doi:10.1016/j.cmet.2014.10.001. PMC 4261644. PMID 25440061.
  30. ^ Gao, Jie; Marosi, Mate; Choi, Jinkuk; Achiro, Jennifer M.; Kim, Sangmok; Li, Sandy; Otis, Klara; Martin, Kelsey C.; Portera-Cailliau, Carlos; Tontonoz, Peter (September 11, 2017). "The E3 ubiquitin ligase IDOL regulates synaptic ApoER2 levels and is important for plasticity and learning". eLife. 6: e29178. doi:10.7554/eLife.29178. PMC 5593505. PMID 28891791.
  31. ^ Rong, Xin; Albert, Carolyn J.; Hong, Cynthia; Duerr, Mark A.; Chamberlain, Brian T.; Tarling, Elizabeth J.; Ito, Ayaka; Gao, Jie; Wang, Bo; Edwards, Peter A.; Jung, Michael E.; Ford, David A.; Tontonoz, Peter (November 5, 2013). "LXRs regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition". Cell Metabolism. 18 (5): 685–697. doi:10.1016/j.cmet.2013.10.002. PMC 3889491. PMID 24206663.
  32. ^ Rong, X.; Wang, B.; Dunham, M. M.; Hedde, P. N.; Wong, J. S.; Gratton, E.; Young, S. G.; Ford, D. A.; Tontonoz, P. (2015). "Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion - PubMed". eLife. 4. doi:10.7554/eLife.06557. PMC 4400582. PMID 25806685.
  33. ^ B, Wang; X, Rong; Ma, Duerr; Dj, Hermanson; Pn, Hedde; Js, Wong; Tq, Vallim; Bf, Cravatt; E, Gratton; Da, Ford; P, Tontonoz (March 8, 2016). "Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet". Cell Metabolism. 23 (3): 492–504. doi:10.1016/j.cmet.2016.01.001. PMC 4785086. PMID 26833026.
  34. ^ a b Sandhu, Jaspreet; Li, Shiqian; Fairall, Louise; Pfisterer, Simon G.; Gurnett, Jennifer E.; Xiao, Xu; Weston, Thomas A.; Vashi, Dipti; Ferrari, Alessandra; Orozco, Jose L.; Hartman, Celine L.; Strugatsky, David; Lee, Stephen D.; He, Cuiwen; Hong, Cynthia; Jiang, Haibo; Bentolila, Laurent A.; Gatta, Alberto T.; Levine, Tim P.; Ferng, Annie; Lee, Richard; Ford, David A.; Young, Stephen G.; Ikonen, Elina; Schwabe, John W. R.; Tontonoz, Peter (October 4, 2018). "Aster Proteins Facilitate Nonvesicular Plasma Membrane to ER Cholesterol Transport in Mammalian Cells". Cell. 175 (2): 514–529.e20. doi:10.1016/j.cell.2018.08.033. PMC 6469685. PMID 30220461.
  35. ^ Xiao, Xu; Kennelly, John Paul; Ferrari, Alessandra; Clifford, Bethan L.; Whang, Emily; Gao, Yajing; Qian, Kevin; Sandhu, Jaspreet; Jarrett, Kelsey E.; Brearley-Sholto, Madelaine C.; Nguyen, Alexander; Nagari, Rohith T.; Lee, Min Sub; Zhang, Sicheng; Weston, Thomas A.; Young, Stephen G.; Bensinger, Steven J.; Villanueva, Claudio J.; de Aguiar Vallim, Thomas Q.; Tontonoz, Peter (January 19, 2023). "Hepatic nonvesicular cholesterol transport is critical for systemic lipid homeostasis". Nature Metabolism. 5 (1): 165–181. doi:10.1038/s42255-022-00722-6. PMC 9995220. PMID 36646756.
  36. ^ Ferrari, Alessandra; Whang, Emily; Xiao, Xu; Kennelly, John P.; Romartinez-Alonso, Beatriz; Mack, Julia J.; Weston, Thomas; Chen, Kai; Kim, Youngjae; Tol, Marcus J.; Bideyan, Lara; Nguyen, Alexander; Gao, Yajing; Cui, Liujuan; Bedard, Alexander H.; Sandhu, Jaspreet; Lee, Stephen D.; Fairall, Louise; Williams, Kevin J.; Song, Wenxin; Munguia, Priscilla; Russell, Robert A.; Martin, Martin G.; Jung, Michael E.; Jiang, Haibo; Schwabe, John W. R.; Young, Stephen G.; Tontonoz, Peter (10 November 2023). "Aster-dependent nonvesicular transport facilitates dietary cholesterol uptake - PubMed". Science. 382 (6671): eadf0966. doi:10.1126/science.adf0966. PMC 11073449. PMID 37943936.
  37. ^ Qian, Kevin; Tol, Marcus J.; Wu, Jin; Uchiyama, Lauren F.; Xiao, Xu; Cui, Liujuan; Bedard, Alexander H.; Weston, Thomas A.; Rajendran, Pradeep S.; Vergnes, Laurent; Shimanaka, Yuta; Yin, Yesheng; Jami-Alahmadi, Yasaman; Cohn, Whitaker; Bajar, Bryce T.; Lin, Chia-Ho; Jin, Benita; Denardo, Laura A.; Black, Douglas L.; Whitelegge, Julian P.; Wohlschlegel, James A.; Reue, Karen; Shivkumar, Kalyanam; Chen, Feng-Jung; Young, Stephen G.; Li, Peng; Tontonoz, Peter (January 2023). "CLSTN3β enforces adipocyte multilocularity to facilitate lipid utilization - PubMed". Nature. 613 (7942): 160–168. doi:10.1038/s41586-022-05507-1. PMC 9995219. PMID 36477540.
  38. ^ "The Havel Lecture". www.asbmb.org.
  39. ^ "NAM names new members". www.asbmb.org.
  40. ^ "National Academy of Medicine selects 3 UCLA professors for membership". Daily Bruin.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Peter_Tontonoz&oldid=1232364854"